Cstone Pharmaceuticals
Clinical trials sponsored by Cstone Pharmaceuticals, explained in plain language.
A biopharmaceutical company focused on developing and commercializing innovative cancer therapies.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
New drug CS5007 targets tough cancers in first human trial
Disease control Recruiting nowThis early-stage trial tests a new drug called CS5007 in people with advanced solid tumors that cannot be removed by surgery. The drug is designed to seek out and attack cancer cells while sparing healthy ones. The study will first find the safest dose and then check if the drug …
Phase: PHASE1 • Sponsor: CStone Pharmaceuticals • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Triple-Action antibody takes on advanced cancers
Disease control Recruiting nowThis study tests a new drug called CS2009, a tri-specific antibody that targets three proteins (PD-1, VEGFA, and CTLA-4) to fight advanced solid tumors. The trial has two phases: first, finding the safest dose, then expanding to see how well it shrinks tumors. About 660 adults wi…
Phase: PHASE1, PHASE2 • Sponsor: CStone Pharmaceuticals • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC